The trial was tailored to evaluate the therapy at multiple ascending dose levels, with three dose administrations per level.

Precision BioSciences reports early PBGENE-HBV trial data showing safety and antiviral activity in chronic Hepatitis B patients, with more results expected in 2025.

Reactive arthritis — perhaps caused ... hepatitis B virus core IgM, hepatitis B virus surface antigen, and hepatitis C virus antibodies were all negative. PCR testing for babesia, ehrlichia ...

Larger antigens, including antigen in immune complexes, can be presented to B cells on the surface of cells, such as dendritic cells, macrophages and follicular dendritic cells (FDCs). These ...

The duration of hepatitis B surface antigen (HBsAg) exposure (indicated by the patient’s age), rather than the quantity of HBsAg, was associated with the level of anti-HBV immune response, in ...

Preterm babies who receive a hepatitis B virus (HBV) vaccine at birth aren't at increased risk of developing a chronic lung disease that affects newborns, according to a new study. The research ...

Hepatitis B (sometimes referred to as hep B) is a liver infection caused by the hepatitis B virus (HBV). It typically causes symptoms like stomach pain, dark urine, fatigue, fever, jaundice (yellowing ...

It should include a "triple" panel of HBsAg, antibodies to HBV surface Ag (anti-HBs), and HBV total core Ag (anti-HBc). Those with positive anti-HBc are at risk for HBVr. AGA's guidance is based ...